• Pulmonary hypertension

Veletri Generic Name & Formulations

General Description

Epoprostenol (as sodium) 0.5mg, 1.5mg; per vial; pwd for IV infusion after reconstitution.

Pharmacological Class

Prostacyclin analogue.

How Supplied

Vial (10mL)—1

Generic Availability


Veletri Indications


Pulmonary arterial hypertension (PAH; WHO Group I) in patients with NYHA Class III or IV symptoms, to improve exercise ability.

Veletri Dosage and Administration


Give by continuous chronic IV infusion through a central venous catheter. Initially 2ng/kg/min; increase in increments of 1–2ng/kg/min at ≥15min intervals based on response. Decrease dose gradually in 2ng/kg/min decrements at ≥15min intervals until dose-limiting effects resolve.


Not established.

Veletri Contraindications


Heart failure due to severe left ventricular systolic dysfunction. Pulmonary edema.

Veletri Boxed Warnings

Not Applicable

Veletri Warnings/Precautions


Avoid abrupt withdrawal or large dose reductions (may cause rebound pulmonary hypertension). Risk of pulmonary embolism or systemic embolism; give anticoagulant therapy unless contraindicated. Monitor BP and heart rate during initiation and after dose changes. Pregnancy. Nursing mothers.

Veletri Pharmacokinetics

See Literature

Veletri Interactions


Hypotensive effects may be potentiated by diuretics, antihypertensive agents, other vasodilators. Increased risk of bleeding with anticoagulants, antiplatelets. May potentiate digoxin concentration; monitor for digoxin toxicity.

Veletri Adverse Reactions

Adverse Reactions

Nausea, vomiting, headache, hypotension, flushing, chest pain, dizziness, bradycardia, dyspnea, abdominal pain, musculoskeletal pain, tachycardia, jaw pain, diarrhea, flu-like symptoms, anxiety/nervousness.

Veletri Clinical Trials

See Literature

Veletri Note

Not Applicable

Veletri Patient Counseling

See Literature